CYP4V2 — cytochrome P450 family 4 subfamily V member 2

The CYP4V2 gene provides instructions for making an enzyme that plays a crucial role in breaking down certain types of fats (lipids) in the body. This enzyme is especially active in the eye, specifically in a layer of cells called the retinal pigment epithelium (RPE), which supports and nourishes the light-sensing cells (photoreceptors) of the retina. The enzyme helps process and clear away the fatty waste products that are constantly produced as the eye detects light. When the CYP4V2 gene is mutated, the enzyme it produces does not work correctly or is missing entirely. As a result, the eye cannot properly break down these fats. The unprocessed fats build up and form tiny, glistening yellow-white crystals in the retina and sometimes in the clear front part of the eye (the cornea). Over time, this buildup of fatty crystals damages the RPE and the photoreceptors, leading to a condition called Bietti crystalline dystrophy (BCD). For patients and families, a diagnosis of BCD means a gradual loss of vision. The condition usually begins in young adulthood with night blindness and a slow narrowing of the visual field. As the disease progresses over decades, it typically leads to severe vision loss or legal blindness. BCD is inherited in an autosomal recessive pattern, meaning a person must inherit two mutated copies of the gene (one from each parent) to develop the disease. Parents who carry only one mutated copy usually do not have symptoms but have a 25% chance of passing the condition to each of their children.

Gene description: CYP4V2 encodes a cytochrome P450 enzyme involved in fatty acid metabolism, particularly in the retina.

Patient and family guide: The CYP4V2 gene provides instructions for making an enzyme that plays a crucial role in breaking down certain types of fats (lipids) in the body. This enzyme is especially active in the eye, specifically in a layer of cells called the retinal pigment epithelium (RPE), which supports and nourishes the light-sensing cells (photoreceptors) of the retina. The enzyme helps process and clear away the fatty waste products that are constantly produced as the eye detects light. When the CYP4V2 gene is mutated, the enzyme it produces does not work correctly or is missing entirely. As a result, the eye cannot properly break down these fats. The unprocessed fats build up and form tiny, glistening yellow-white crystals in the retina and sometimes in the clear front part of the eye (the cornea). Over time, this buildup of fatty crystals damages the RPE and the photoreceptors, leading to a condition called Bietti crystalline dystrophy (BCD). For patients and families, a diagnosis of BCD means a gradual loss of vision. The condition usually begins in young adulthood with night blindness and a slow narrowing of the visual field. As the disease progresses over decades, it typically leads to severe vision loss or legal blindness. BCD is inherited in an autosomal recessive pattern, meaning a person must inherit two mutated copies of the gene (one from each parent) to develop the disease. Parents who carry only one mutated copy usually do not have symptoms but have a 25% chance of passing the condition to each of their children.

Gene function: CYP4V2 is thought to be involved in the metabolism of very long-chain fatty acids, which are crucial components of photoreceptor outer segment membranes. Its enzymatic activity is essential for maintaining lipid homeostasis in the retina, preventing the accumulation of toxic lipid byproducts, and supporting the structural integrity and function of photoreceptor cells, which are vital for vision.

Protein structure: The CYP4V2 gene encodes a 525-amino acid protein that belongs to the cytochrome P450 family 4, subfamily V, member 2. Like other cytochrome P450 enzymes, the CYP4V2 protein is a membrane-bound hemethiolate monooxygenase. Its structure is characterized by several conserved domains essential for its function, including a transmembrane domain at the N-terminus that anchors the protein to the endoplasmic reticulum membrane, and a highly conserved heme-binding domain near the C-terminus. The core structure of the CYP4V2 protein consists of multiple alpha-helices and beta-sheets that fold to create a catalytic pocket where the heme group is bound. The heme iron is coordinated by a conserved cysteine residue, which is critical for the enzyme's oxidative activity. The protein must properly fold and assemble within the endoplasmic reticulum to interact with its redox partner, cytochrome P450 reductase, which supplies the electrons necessary for the hydroxylation of fatty acid substrates. Mutations in CYP4V2 often disrupt these structural domains, leading to misfolding, loss of heme binding, or inability to interact with the reductase.

Molecular function: The CYP4V2 gene encodes a member of the cytochrome P450 superfamily of enzymes, specifically a hemethiolate monooxygenase. These enzymes are crucial for the oxidation of various substrates in metabolic pathways. CYP4V2 functions primarily as a selective omega-hydroxylase of saturated, medium-chain, and polyunsaturated fatty acids (PUFAs). It exhibits relatively high catalytic efficiency toward specific fatty acids, such as myristic acid, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA). In the retinal pigment epithelium (RPE), CYP4V2 plays a critical role in lipid homeostasis and the processing of outer segment membranes shed by photoreceptors. The RPE is responsible for phagocytosing and degrading these lipid-rich outer segments daily. CYP4V2 is involved in the degradation and clearance of these lipids. When CYP4V2 is mutated and dysfunctional, it leads to a defect in lipid metabolism, resulting in the systemic and localized accumulation of specific lipid compounds. This metabolic bottleneck causes the formation of the characteristic lipid-rich crystalline deposits within the RPE and cornea, ultimately leading to cellular toxicity, RPE cell death, and secondary photoreceptor degeneration.

Expression pattern: The CYP4V2 gene is widely expressed across various human tissues, but it exhibits particularly high expression levels in the eye. Within the ocular tissues, CYP4V2 is predominantly expressed in the retinal pigment epithelium (RPE) and the cornea. The RPE is a monolayer of cells critical for the maintenance and survival of photoreceptors, and the high expression of CYP4V2 in these cells underscores its vital role in retinal lipid homeostasis. In addition to the RPE, CYP4V2 is also expressed in the corneal epithelium, which correlates with the clinical observation of crystalline deposits in the cornea of some BCD patients. While it is expressed at lower levels in other systemic tissues such as the liver, heart, and lymphocytes, the primary pathology associated with CYP4V2 mutations is localized to the eye, suggesting that the retina and cornea are particularly sensitive to the loss of its specific lipid-metabolizing functions.

Mutation spectrum: The mutation spectrum of the CYP4V2 gene is diverse, with over 100 pathogenic variants identified to date. These include missense, nonsense, frameshift, splice-site mutations, and small deletions or insertions. Missense mutations are the most common type, often affecting highly conserved amino acid residues within the functional domains of the cytochrome P450 enzyme, thereby impairing its catalytic activity or structural stability. A significant feature of the CYP4V2 mutation spectrum is the presence of founder mutations in specific populations. The most notable is the complex rearrangement c.802-8_810del17insGC (often referred to as skipping of exon 7), which is highly prevalent in East Asian populations, particularly among Chinese and Japanese patients. This mutation accounts for a large proportion of BCD cases in these regions. Other recurrent mutations have been identified in different ethnic groups, highlighting the genetic heterogeneity of the disease across global populations.

Pathogenic variants: 1. c.802-8_810del17insGC (p.Val268_Glu270delinsGly) - This complex deletion-insertion variant leads to the skipping of exon 7. It is the most common founder mutation in East Asian populations (Chinese and Japanese) and is associated with a severe phenotype and earlier age of onset. 2. c.1091-2A>G - A common splice-site mutation that disrupts normal mRNA splicing, leading to a truncated or non-functional protein. It is frequently observed in compound heterozygosity with other variants. 3. c.332T>C (p.Ile111Thr) - A missense mutation primarily reported in European populations. It has been associated with a specific phenotype involving central corneal crystalline deposits and may exhibit a dose-dependent effect in carriers. 4. c.1226C>A (p.Pro409His) - A missense mutation that alters a conserved proline residue, likely disrupting the structural integrity or functional activity of the enzyme. 5. c.992A>C (p.His331Pro) - A missense mutation located near the critical heme-binding domain of the cytochrome P450 enzyme, severely impairing its catalytic function.

Clinical significance: Mutations in the CYP4V2 gene cause Bietti crystalline corneoretinal dystrophy (BCD), a rare autosomal recessive inherited retinal disease. The condition typically manifests in the second to third decade of life, though the age of onset can range from the early teens to beyond the third decade. Initial symptoms usually include night blindness (nyctalopia) and progressive vision loss. As the disease advances, patients experience constricted visual fields, paracentral or central scotomas, and a significant decline in visual acuity. Clinically, BCD is characterized by the presence of numerous small, glistening yellow-white crystalline lipid deposits scattered throughout the posterior pole of the retina, sometimes extending to the midperiphery. These deposits are accompanied by progressive atrophy of the retinal pigment epithelium (RPE), photoreceptors, and choriocapillaris. In about one-quarter to one-third of patients, similar crystalline deposits can also be observed in the corneal limbus. The disease severity and progression rate are highly variable, even among individuals with the same mutations. Most patients progress to legal blindness by their fifth or sixth decade of life, although central vision may be spared until the late stages in some cases. Additional complications can include cataracts, macular edema, and choroidal neovascularization.

Inheritance: Autosomal Recessive

Chromosomal location: 4q28.2

Genotype-phenotype correlations: Genotype-phenotype correlations in Bietti crystalline dystrophy are complex and highly variable. The severity of the disease, age of onset, and rate of progression can differ significantly even among individuals carrying the same CYP4V2 mutations, suggesting the influence of genetic modifiers or environmental factors. However, some broad correlations have been observed. For instance, patients who are homozygous or compound heterozygous for the common founder mutation c.802-8_810del17insGC tend to have an earlier age of onset and a more severe clinical phenotype, characterized by worse electrophysiological responses and more extensive retinal thinning, compared to those with missense mutations. Conversely, certain missense variants may result in a milder phenotype due to the retention of partial enzymatic activity. For example, the c.332T>C (p.Ile111Thr) variant, reported primarily in European populations, has been associated with an unusual central and paracentral corneal distribution of crystalline deposits without limbic involvement, and may exhibit a dose-dependent phenotype where heterozygous carriers show mild, late-onset corneal deposits. Despite these observations, the high degree of clinical heterogeneity makes it challenging to predict the exact disease course based solely on the CYP4V2 genotype.

Research and therapeutic approaches: Currently, there are no FDA-approved treatments or cures for Bietti crystalline dystrophy (BCD). Management is primarily supportive, focusing on low vision aids, regular monitoring for complications like choroidal neovascularization or macular edema, and providing genetic counseling. However, significant progress is being made in the development of targeted therapies, particularly gene replacement therapy, which aims to deliver a functional copy of the CYP4V2 gene to the affected retinal cells. Gene therapy for BCD has shown highly promising results in preclinical models and has recently advanced to human clinical trials. Adeno-associated virus (AAV) vectors are typically used to deliver the CYP4V2 transgene via subretinal injection, targeting the retinal pigment epithelium (RPE). A landmark Phase 1/2 clinical trial (NCT04722107) evaluating an AAV-mediated gene therapy for BCD reported encouraging safety and efficacy data, with a significant proportion of treated eyes showing improvements in best-corrected visual acuity (BCVA) over a one-year follow-up period. Other therapeutic avenues being explored in preclinical stages include lipid-lowering agents and metabolic modulators aimed at bypassing the enzymatic defect, though gene therapy remains the most advanced and promising approach in the pipeline.

Diagnostic testing: Diagnosis of Bietti crystalline dystrophy is typically initiated based on clinical findings, including the characteristic yellow-white crystalline deposits in the retina and cornea, along with progressive RPE and choriocapillaris atrophy. Optical coherence tomography (OCT) and fundus autofluorescence (FAF) are valuable imaging modalities for visualizing these deposits and monitoring disease progression. However, because the clinical presentation can overlap with other inherited retinal dystrophies, molecular genetic testing is essential for a definitive diagnosis. Genetic testing for BCD involves identifying biallelic pathogenic variants in the CYP4V2 gene. This is often accomplished through targeted gene panels for inherited retinal diseases or whole exome sequencing (WES). Genetic counseling is highly recommended for affected individuals and their families to discuss the autosomal recessive inheritance pattern, the variable prognosis, and the potential risks to offspring. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the pathogenic variants in the family are known.

Animal models: Animal models have been crucial for understanding the pathogenesis of Bietti crystalline dystrophy (BCD) and testing potential therapies. In zebrafish, the homologous genes cyp4v7 and cyp4v8 have been knocked out using CRISPR/Cas9 technology. These knockout zebrafish lines exhibit accumulation of lipid droplets and morphological changes in photoreceptors, mimicking the lipid metabolism defects seen in human patients. Mouse models have also been developed to study CYP4V2 function. While early Cyp4v3 (the mouse ortholog of human CYP4V2) knockout mice did not fully replicate the severe retinal degeneration seen in humans, they did show abnormalities in lipid metabolism and accumulation of lipid deposits in the retinal pigment epithelium (RPE) and cornea. More recently, induced pluripotent stem cell (iPSC)-derived RPE models from BCD patients have been utilized to demonstrate defective lipid metabolism, lysosomal dysfunction, and impaired autophagy, providing a robust humanized in vitro model for testing gene therapies.

Population genetics: Bietti crystalline dystrophy is generally considered a rare disease globally, but its prevalence varies significantly among different populations. It is notably more common in individuals of East Asian descent, particularly in Chinese and Japanese populations, where it is estimated to account for up to 3% of all non-syndromic retinitis pigmentosa cases. This higher prevalence is largely driven by the founder mutation c.802-8_810del17insGC, which has a high carrier frequency in these groups. While less common, BCD has also been reported in individuals of European, Middle Eastern, African, and American descent, often associated with different, population-specific pathogenic variants. The estimated worldwide prevalence of BCD is roughly 1 in 67,000, though it may be underdiagnosed due to clinical overlap with other retinal dystrophies.

Selected references: 1. Li A, et al. Bietti crystalline corneoretinal dystrophy is caused by mutations in the novel gene CYP4V2. Am J Hum Genet. 2004;74(5):817-826. PMID: 15042513 2. Nakano M, et al. Expression and characterization of CYP4V2 as a fatty acid omega-hydroxylase. Drug Metab Dispos. 2009;37(11):2119-2122. PMID: 19661213 3. Xiao X, et al. Identification of CYP4V2 mutation in 21 families and overview of mutation spectrum in Bietti crystalline corneoretinal dystrophy. Biochem Biophys Res Commun. 2011;409(2):181-186. PMID: 21565175 4. Wang J, et al. Gene replacement therapy in Bietti crystalline corneoretinal dystrophy. Signal Transduct Target Ther. 2024;9(1):103. PMID: 38658535 5. Jia R, et al. Unravelling CYP4V2: Clinical features, genetic insights, pathogenic mechanisms, and gene therapy in Bietti crystalline corneoretinal dystrophy. Prog Retin Eye Res. 2025;104:101288. PMID: 39848280 6. Astuti GD, et al. Comprehensive genotyping reveals RPE65 as the most frequently mutated gene in Leber congenital amaurosis in Denmark. Eur J Hum Genet. 2015;23(8):1071-1079. PMID: 25424714 7. Zhang H, et al. Quickly diagnosing Bietti crystalline dystrophy with deep learning. Artif Intell Med. 2024;148:102768. PMID: 38341234